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Antisense oligonucleotides are short, single-stranded nucleic acid analogues that can
interfere with pre-messenger RNA (pre-mRNA) processing and induce excision of a
targeted exon from the mature transcript. When developing a panel of antisense
oligonucleotides to skip every dystrophin exon, we found great variation in splice switching
efficiencies, with some antisense oligonucleotides ineffective, even when directed to
canonical splice sites and transfected into cells at high concentrations. In this study, we re-
evaluated some of these ineffective antisense oligonucleotide sequences after incorporation
of locked nucleic acid residues to increase annealing potential. Antisense oligonucleotides
targeting exons 16, 23, and 51 of human DMD transcripts were synthesized as two different
chemistries, 2′-O-methyl modified bases on a phosphorothioate backbone or mixmers
containing several locked nucleic acid residues, which were then transfected into primary
human myotubes, and DMD transcripts were analyzed for exon skipping. The ineffective 2′-
O-methyl modified antisense oligonucleotides induced no detectable exon skipping, while all
corresponding mixmers did induce excision of the targeted exons. Interestingly, the mixmer
targetingexon51 induced twounexpected transcripts arising frompartial skippingof exon51
with retention of 95 or 188 bases from the 5′ region of exon 51. These results indicated that
locked nucleic acid/2′-O-methyl mixmers are more effective at inducing exon skipping,
however, this improvement may come at the cost of activating alternative cryptic splice sites
and off-target effects on gene expression.
Keywords: DMD, antisense oligonucleotide, locked nucleic acid, locked nucleic acid/2′-O-methyl mixmer, cryptic
splice siteINTRODUCTION
Mutations in the DMD gene are responsible for Duchenne (DMD) and Becker (BMD) muscular
dystrophies. The more severe DMD is typically associated with frameshifting deletions, duplications,
or insertions, or nonsense mutations that cause disruption of the open reading frame (ORF). Most
mutations that do not disrupt the ORF produce an internally truncated but partially functionalDecember 2019 | Volume 10 | Article 12491
Zaw et al. Enhancing Antisense Oligonucleotide Splice Switchingprotein, resulting in the milder BMD phenotype (Monaco et al.,
1988). This spectrum of disease severity underlies the
development of therapeutic interventions such as antisense
oligonucleotide (AO) induced targeted exon skipping to treat
DMD (Fletcher et al., 2017; Stein and Castanotto, 2017).
AOs are short, single-stranded nucleic acid analogues that are
designed to anneal to a messenger RNA (mRNA) or pre-mRNA
through Watson–Crick base pairing interactions and, depending
on the base and backbone chemistries, induce a variety of
mechanisms to alter the gene expression. AO induced splice-
switching strategies to skip one or more specific exons, with
restoration of the ORF and expression of dystrophin with
improved function has been explored as a treatment for DMD.
Exondys 51 (Sarepta Therapeutics), a phosphorodiamidate
morpholino oligomer targeting exon 51, has been given
accelerated approval by the US Food and Drug Administration
(FDA) for the treatment of DMD (Syed, 2016).
Strategies to improveAOpotency throughmore efficient cellular
uptake or increased stability and specificity of AOs are continually
being explored to develop compounds that would confer optimal
therapeutic effects. Approaches to enhance AO potency involve
chemical modifications of the phosphate backbone or at the 2′
position of the ribose sugar, such as 2′-O-methyl (2′-OMe) or
locked nucleic acid (LNA) in order to increase binding affinity and
resistance against nuclease degradation (Figure 1A). LNA-
modified oligonucleotides show a high binding affinity and
increased stability against nuclease degradation compared to only
the 2′-OMe modification (Kierzek et al., 2009).
When developing a panel of AOs to skip all dystrophin exons,
remarkably we found that two out of three compounds could
induce some level of exon skipping, albeit at variable efficiencies.
During development of splice switching AOs, targeting many of
the canonical donor or acceptor splice sites in the dystrophin
primary transcript appeared to be largely ineffective, especially
when compared to targeting intra-exonic splice enhancer motifs
(Adams et al., 2007). The current study aimed to ascertain if
increasing the annealing potential of an AO by incorporating
LNA residues at selected positions could influence splicing. We
selected three examples of acceptor or donor splice sites that
were ineffective as 2′-OMe AO target sites. We found that the
LNA/2′-OMe AO mixmers with increased annealing potential
were capable of modifying pre-mRNA processing, indicating that
these AOs could act as splice switching compounds if the
strength of annealing was sufficiently increased. However, in
one case, multiple transcripts were induced due to the activation
of intra-exonic cryptic splice sites, suggesting that enhanced
annealing may compromise splice switching specificity.MATERIALS AND METHODS
Design and Synthesis of Chemically
Modified AOs
2′-OMe AOs, previously designed, evaluated, and found to be
inactive with respect to inducing skipping of human
dystrophin exons 16, 23, and 51 (Harding et al., 2007;Frontiers in Genetics | www.frontiersin.org 2Mitrpant et al., 2009), were resynthesized in house on a GE
AKTA Oligopilot plus 10 (GE Healthcare Life Sciences)
oligonucleotide synthesizer, as described previously using the 1
mmol thioate protocol (Le et al., 2017). The mixmers
incorporating the LNAs are described in Table 1 and were also
synthesized in house (Le et al., 2017).Cell Culture and Transfection
Primary human myoblasts, obtained after informed consent and
approved by the Murdoch University human ethics committee
(#2013_156), were cultured and differentiated into myotubes as
described by Rando and Blau (Rando and Blau, 1994) with minor
modifications (Harding et al., 2007). Briefly, myoblasts were
seeded on 24-well plates coated with poly-D-lysine (Merck
Millipore), and Matrigel (Corning, supplied through In Vitro
Technologies) at a density of 30,000 cells/well. Cells were
differentiated into myotubes in 5% horse serum low glucoseFIGURE 1 | Analysis of exon skipping efficiency using LNA/2′-OMe (locked
nucleic acid/2′-O-methyl) mixmers and 2′-OMe modified antisense
oligonucleotides (AOs). (A) Structure of LNA; 2′ oxygen and 4′ carbon of the
sugar ring is connected by an extra bridge (left) and 2′-OMe; a methyl group is
added to the 2′ hydroxyl of the sugar ring (right). The backbone is modified with a
phosphorothioate linkage where the non-bridging oxygen is replaced with a
sulfur. (B) Reverse transcriptase polymerase chain reaction (RT-PCR) analysis of
RNA extracted from primary human myotubes cultures transfected with LNA/2′-
OMe mixmers or 2′-OMe. All the mixmers induced skipping of the targeted
exons, while 2′-OMe AOs showed no exon skipping. The mixmer targeting exon
51 produced two RT-PCR amplicons in addition to the expected full length and
exon 51–skipped transcripts. The arrowheads indicate decreasing AO
concentration (200, 100, 50, and 25 nM). (UT: untreated cells, N: no template
negative RT-PCR control, 100bp: DNA ladder).December 2019 | Volume 10 | Article 1249
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Scientific) by incubating at 37°C in 5% CO2 for 48 h. All 2′-OMe
AOs and mixmers were transfected into differentiated myotubes
in Opti-MEM (Invitrogen) as cationic lipoplexes with
Lipofectamine 2000 reagent at 1:1 w:w ratio, according to the
manufacturer’s instructions (Invitrogen) in a final transfection
volume of 500 µl/well in a 24-well plate. Transfected cells were
incubated for 48 h before total RNA extraction.RNA Extraction and RT-PCR
RNA extraction was carried out using the MagMAX-96 Total
RNA Isolation Kit (Life Technologies), according to the
manufacturer’s instructions. RT-PCRs were performed using
the One-Step SuperScript III RT-PCR kit (Life Technologies)
as per manufacturer’s instructions. The temperature profile was
55°C for 30 min, 94°C for 2 min, followed by 35 cycles of 94°C
for 15 s, 55°C for 30 s, and 68°C for 1 min 10 s. RT-PCR
products were separated on 2% agarose gels in Tris-acetate-
ethylenediaminetetraacetic acid (EDTA) buffer, and the images
were captured on a Fusion FX gel documentation system (Vilber
Lourmat, Marne-la-Vallee, France).Band-Stab PCR and Sequencing
Individual bands representing RT-PCR amplicons were purified and
amplified by band-stab PCR (Wilton et al., 1997) using AmpliTaq
GoldDNAPolymerases (Thermo Fisher Scientific) with the thermal
profile of 94°C for 5 min followed by 25 cycles of 94°C for 15 s, 50°CFrontiers in Genetics | www.frontiersin.org 3for 15 s, 72°C for 1 min with the final extension of 72°C for 5 min.
Amplicon sequences were identified by Sanger sequencing at the
Australian Genome Research Facility (AGRF, Perth, Australia). The
nucleotide sequences were deposited at GenBank and available as
accession numbers MN490082–MN490085.
In Silico Analysis
The natural and potential donor splice sites of DMD exon 51
were analyzed using Human Splicing Finder 3.1 (http://www.
umd.be/HSF3/HSF.shtml) (Desmet et al., 2009).RESULTS
AO Synthesis and Transfection
In this study, we used AO sequences that had been designed to
induce skipping of exons 16, 23, and 51 from the human
dystrophin gene transcript, but were previously reported to be
largely ineffective when transfected into cells as 2′-OMe modified
compounds on a phosphorothioate backbone. These sequences
were re-synthesized as 2′-OMe AOs and as respective LNA-2′-
OMe “mixmers” on a phosphorothioate backbone, a 20-mer for
exon 16 and 25-mers for exons 23 and 51, as shown in Table 1.
Primary human myoblasts obtained after informed consent and
approved by the Murdoch University human ethics committee
(#2013_156) were cultured on 24-well plates, differentiated over
48 h, and transfected with AO cationic lipoplexes at 200, 100, 50,
and 25 nM concentrations. The cells transfected with either 2′-TABLE 1 | Sequences of AOs used in this study.
Sequence LNA/2′-OMe Mixmers 2′-OMe
H16A (–07+13) CCGCUUUUAAAACCUGUUAA CCGCUUUUAAAACCUGUUAA
H23D (+07–18) AGUAAAAUCUUGAAUUACCUGAAUU AGUAAAAUCUUGAAUUACCUGAAUU
H51D (+07–18) UAUCAUUUUUUCUCAUACCUUCUGC UAUCAUUUUUUCUCAUACCUUCUGCDeceLNA nucleotide monomers are represented as bold characters.FIGURE 2 | Sequencing of individual reverse transcriptase polymerase chain reaction (RT-PCR) products produced by the mixmer targeting exon 51. The two
additional amplicons represent incomplete skipping of exon 51, with retention of the first 95 or 188 bases of exon 51.mber 2019 | Volume 10 | Article 1249
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and showed no obvious signs of toxicity or cell death at
these concentrations.
Evaluation of AO Efficiency
The cells were collected 48 h after transfection and analyzed for
respectiveDMD exon skipping by reverse transcriptase polymerase
chain reaction (RT-PCR). As anticipated, the 2′-OMe AOs did not
induce exon skipping while all the LNA/2′-OMemixmers induced
consistent skipping of the targeted exons at all tested concentrations
(Figure1B). Interestingly, theLNA/2′-OMemixmer targetingexon
51 induced two transcript products in additional to the predicted
full-length products (988 bp) and exon 51–skipped (755 bp)
transcript product. The 2′-OMe AO directed at dystrophin exon
51 donor splice site induced very weak exon skipping and also low
levels of the 943 and 850 bp amplicons.
Identification of Full-Length and Skipped
Transcripts
The individual products were purified by band-stab PCR (Wilton
et al., 1997) and identified by direct DNA sequencing that
confirmed the identity of the full-length and induced exon-
skipped amplicons (Figure 2). The additional products
generated predominantly by the exon 51 LNA/2′-OMe mixmer
arose from activation of cryptic donor splice sites, with retention
of 95 or 188 bases from the beginning of exon 51 (850 and 943 bp
amplicons respectively). The sequences are available at GenBank
with the accession numbers MN490082–MN490085.Frontiers in Genetics | www.frontiersin.org 4Analysis of Activated Cryptic Splice Sites
The cryptic splice sites activated by the mixmer targeting exon 51
are potential splice sites within DMD exon 51 (Figure 3) as
predicted by Human Splicing Finder 3.1 (HSF) (http://www.
umd.be/HSF3/HSF.shtml) (Desmet et al., 2009). Both cryptic
donor splice sites included the canonical donor splice site
sequence, ‘GT’ at the 5′ end of the “intron.” The HSF scores
for cryptic donor sites 1 and 2 are 77.42 and 84.8 respectively,
which are high and close to the natural splice site score, 87.91. In
the maximum entropy model, both cryptic sites are also the only
positions predicted to be potential splice sites in addition to the
natural donor site (Yeo and Burge, 2004). Interestingly, the splice
site score for the cryptic donor site 2 is higher than the cryptic
donor site 1 in HSF score, although the cryptic donor site 1 has a
higher score in the maximum entropy model.DISCUSSION
The most common consequence of mutations of the canonical
donor or acceptor splice sites is exon skipping. However, the
majority of dystrophin exons appeared unresponsive to splice
switching AOs targeting these motifs, and only 2 exons out of the
77 were identified with the donor splice sites being optimal
targets (Wilton et al., 2007). In this study, we modified three
previously reported inactive AO sequences identified by
ourselves and others, with LNA incorporation to improve the
annealing affinity, and revisited their ability to induce exonFIGURE 3 | Potential splice sites for human DMD exon 51 predicted by Human Splicing Finder 3.1 (HSF) indicating the natural donor splice site and the two cryptic
donor splice sites activated by the mixmers. The splice sites scores are predicted for each site (Yeo and Burge, 2004; Desmet et al., 2009). The splice site score for
the cryptic donor site 2 is higher than the cryptic donor site 1 in HSF score, although the cryptic donor site 1 has a higher score in the maximum entropy model.December 2019 | Volume 10 | Article 1249
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2′-OMe AOs showed no or poor exon skipping after
transfection, while all mixmers induced readily detectable
skipping of the targeted exons.
During optimization of AOs to excise DMD exon 16, we
previously demonstrated that AOs targeting the acceptor site and
adjacent putative exonic splicing enhance sites could induce marked
exon skipping, as long as the AOs were 25-mers or longer (Harding
et al., 2007). While overlapping 25-mer and 31-mers induced robust
exon 16 skipping, a shorter 20-mer common to all sequences was
ineffective. Since shorter AOs are more efficiently and economically
synthesized, we aim to identify the shortest sequence capable of
inducing robust exon skipping, but in this instance, the 20-mer did
not have sufficient annealing strength to the target because of the
low ‘GC’ content (Harding et al., 2007). Incorporation of LNAs into
this short and inactive 20-mer resulted in increased annealing
potential and relatively robust exon skipping. This suggested that
the limitation of the original 20-mer was due to weak hybridization.
A similar trend was observed for AO induced human
dystrophin exon 23 skipping. We previously reported refining
2′-OMe AOs designed to induce exon 23 skipping and restore
dystrophin expression in the mdx mouse (Mann et al., 2002). In
subsequent studies, we found that the optimal annealing
coordinates to skip mouse dystrophin exon 23, H23D (+07–
18), were not an effective target for excising human dystrophin
exon 23 (Mitrpant et al., 2009). In this study, we synthesized the
same sequence as a LNA/2′-OMe mixmer, and exon skipping
was observed when AO was applied to cultured human
myoblasts. Nevertheless, this increased annealing potential only
resulted in modest levels of exon skipping and would not be
considered for clinical application.
Dystrophin exon 51 was selected as the exon target for the first
DMD exon skipping clinical trials since excising this exon would be
relevant to the largest subset of DMD patients (Aartsma-Rus et al.,
2009; Bladen et al., 2015). During the pre-clinical development of
Eteplirsen, all the oligomers targeting the donor splice site of human
dystrophin exon 51were found to be largely ineffective (Arechavala-
Gomezaet al., 2007).A25-mer2′-OMeAO,H51D(+08–17), failed to
skip exon51,whereas anotherAO, a 23-merwithhigherGCcontent,
H51D(+16–07), induced only weak exon skipping (Harding et al.,
2007). We resynthesized the AO sequence H51D (+07–18) as a
mixmerandshowed inductionof threedifferent transcripts: complete
skipping of exon 51 together with two other transcripts produced by
the activation of intra-exonic cryptic donor sites. The levels of
complete exon 51 skipping were modest, and thus, such an
approach would not be clinically applicable to restore the readingFrontiers in Genetics | www.frontiersin.org 5frame. One of the few examples of activation of cryptic splice sites in
the dystrophin gene transcript was in exon 53 of the mouse
dystrophin gene, 77 bases upstream of the normal donor splice site
(Mitrpant et al., 2009). We anticipated that cryptic splice site
activation would be far more common than we have actually
encountered to date.
Our results show that the incorporation of LNA bases into the
AOs increased the annealing potential and transformed inactive
antisense sequences into active AOs. However, one significant
concern that must be investigated is the extent to which cryptic
splice sites are activated, leading to partial exon skipping. LNA-fully-
modified AOs containing up to three mismatches induced
dystrophin exon 46 skipping in DMD patient cells, indicating low
sequence specificity, with the possibility of off-target binding
potential (Aartsma-Rus et al., 2004). In addition, gapmers modified
with LNAs show acute hepatotoxicity in mice (Kasuya et al., 2016).
We andothers have previously reported thatAOson a fullymodified
phosphorothioate backbone recruited nuclear proteins involved in
RNAprocessing and induced global disturbance of cellular processes
(Shen et al., 2014; Flynn et al., 2018).
In conclusion, we show that the incorporation of LNAs into
2′-OMe antisense sequences increased their potency as steric
blockers of splicing, thereby making the inactive active. However,
this enhancement came at a cost in efficiency and specificity due
to activation of cryptic splicing, raising the risk of adverse and
off-target effects elsewhere in the human transcriptome.DATA AVAILABILITY STATEMENT
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